- Home
- PMN
as 11-15-2024 4:00pm EST
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
| Founded: | 2004 | Country: | Canada |
| Employees: | N/A | City: | TORONTO |
| Market Cap: | 32.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 89.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.92 - $3.10 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ProMIS Neurosciences Inc. (ON) (PMN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | PMN | Director | Sep 20 '24 | Buy | $1.28 | 200,000 | $255,750.00 | 68,333 | |
| GORDON MICHAEL S | PMN | 10% Owner | Sep 16 '24 | Buy | $1.31 | 93,223 | $116,880.03 | 76,931 |
Latest ProMIS Neurosciences Inc. (ON) News
PMN Breaking Stock News: Dive into PMN Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
5 days ago
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
GlobeNewswire
18 days ago
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
GlobeNewswire
2 months ago
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
GlobeNewswire
2 months ago
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
3 months ago
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
3 months ago
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
GlobeNewswire
4 months ago
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
Compare PMN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PMN ProMIS Neurosciences Inc. (ON) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.